List of Tekturna drug patents

Tekturna is owned by Noden Pharma.

Tekturna contains Aliskiren Hemifumarate.

Tekturna has a total of 2 drug patents out of which 0 drug patents have expired.

Tekturna was authorised for market use on 05 March, 2007.

Tekturna is available in tablet;oral dosage forms.

The generics of Tekturna are possible to be released after 19 August, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617595 NODEN PHARMA Galenic formulations of organic compounds
Feb, 2026

(3 years from now)

US8617595

(Pediatric)

NODEN PHARMA Galenic formulations of organic compounds
Aug, 2026

(3 years from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient

Market Authorisation Date: 05 March, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TEKTURNA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in